Gujarat Inject (Kerala) Ltd (GUJINJEC) — shareholding pattern, promoter holding, financials and share price
About Gujarat Inject (Kerala) Ltd (GUJINJEC)
Gujarat Inject (Kerala) Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as GUJINJEC and on the BSE under scrip code 524238. Its ISIN is INE659F01022.
Incorporated in 1991, Gujarat Inject Kerala Ltd manufactures pharmaceutical products
Gujarat Inject Kerala Limited, established in 1991, is primarily engaged in the production of IV fluids, having commenced operations in 2005.
The company operates in the pharmaceutical sector, focusing on essential medical products used across hospitals and clinics.
Listed peers in Pharmaceuticals: Kerala Ayurveda Ltd, Coral Laboratories Ltd, Syschem (India) Ltd, Brooks Laboratories Ltd, Achyut Healthcare Ltd, Accretion Nutraveda Ltd.
Valuation & Returns
10 Jul 2026At ₹13.65 a share on 10 Jul 2026, Gujarat Inject (Kerala) Ltd (GUJINJEC) was valued at a price-to-earnings ratio of 10.99x against an industry P/E of 36.41x and a price-to-book of 2x on a book value of ₹6.83 per share as of Mar 2025. Solomo computes return on equity of 18.18% and return on capital employed of 25.07% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 10.99x
- Industry P/E
- 36.41x
- P/B
- 2x
- EPS (TTM)
- ₹1.24
- Book value / share
- ₹6.83
- ROE
- 18.18%
- ROCE
- 25.07%
- ROA
- 15.23%
- Debt / equity
- 0x
- Dividend yield
- 0%
- EBITDA margin
- 6.91%
- 52-week range
- ₹1.9 – ₹14.3
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Gujarat Inject (Kerala) Ltd (GUJINJEC) reported revenue of ₹36.32 crore, net profit of ₹1.81 crore and earnings per share of ₹0.12. That compares with revenue of ₹19.05 crore and net profit of ₹1.02 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Jun 2026, revenue was ₹12.45 crore and net profit ₹1.25 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 0.02 | 0.17 | 5.79 | 19.05 | 36.32 |
| Net profit (₹ cr) | 0 | 0.04 | 0.08 | 1.02 | 1.81 |
| EPS (₹) | 0 | 0.01 | 0.01 | 0.07 | 0.12 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 118.72% | - | 844.56% | 229.02% |
| Profit growth | 138.50% | 440.75% | 672.12% | - |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 0% of Gujarat Inject (Kerala) Ltd (GUJINJEC) (unchanged from the previous quarter). Market capitalisation was ₹20 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: MINA SURENDRA SHAH 5.68%, PATADIYA CHIRAGKUMAR RAJESHKUMAR 5.37%, UMESHBHAI RAJESHBHAI PATADIYA 4.88%, Radadiya chintanbhai anilbhai 4.74%, HARDIKKUMAR ANILBHAI RADADIYA 4.16%, SHASHANK VYAS 3.63%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 0% | - | - | - | 100% |
| Mar 2026 | 0% | - | - | - | 100% |
| Dec 2025 | 0% | - | - | - | 100% |
| Sep 2025 | 0% | - | - | - | 100% |
| Jun 2025 | 0% | - | - | - | 100% |
| Mar 2025 | 0% | - | - | - | 100% |
| Dec 2024 | 0% | - | - | 0% | 100% |
| Sep 2024 | 0% | - | - | 0% | 100% |